Hutchmed has confirmed that regulatory filings for Orpathys plus Tagrisso have been accepted for review in Europe and Japan.
Hansa Biopharma has announced positive data from the European Post‑Authorization Efficacy and Safety study of Idefirix, ...
Hutchmed has announced positive phase 3 results from the SANOVO trial evaluating ORPATHYS plus TAGRISSO in treatment‑naïve ...
Patients with oligometastatic non‑small cell lung cancer lived significantly longer without disease progression when radiotherapy was added to standard systemic therapy, according to new phase 2 data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results